Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

MBX Biosciences (MBX) Receivables - Other (2023 - 2026)

MBX Biosciences has reported Receivables - Other over the past 4 years, most recently at $3.2 million for Q1 2026.

  • Quarterly results put Receivables - Other at $3.2 million for Q1 2026, up 127.94% from a year ago — trailing twelve months through Mar 2026 was $3.2 million (up 127.94% YoY), and the annual figure for FY2025 was $2.1 million, up 210.85%.
  • Receivables - Other reached $3.2 million in Q1 2026 per MBX's latest filing, up from $2.1 million in the prior quarter.
  • Across five years, Receivables - Other topped out at $3.2 million in Q1 2026 and bottomed at $208000.0 in Q4 2023.
  • Median Receivables - Other over the past 4 years was $1.1 million (2024), compared with a mean of $1.3 million.
  • The largest annual shift saw Receivables - Other soared 227.88% in 2024 before it surged 80.42% in 2025.
  • Over 4 years, Receivables - Other stood at $208000.0 in 2023, then skyrocketed by 227.88% to $682000.0 in 2024, then surged by 210.85% to $2.1 million in 2025, then soared by 48.92% to $3.2 million in 2026.
  • Business Quant data shows Receivables - Other for MBX at $3.2 million in Q1 2026, $2.1 million in Q4 2025, and $1.5 million in Q3 2025.